RBCC: Insurance Companies, Researchers Drive Growth in Personalized Medicine

Before you go, we thought you'd like these...
Before you go close icon

RBCC: Insurance Companies, Researchers Drive Growth in Personalized Medicine

NOKOMIS, Fla.--(BUSINESS WIRE)-- As Rainbow Coral Corp. (OTCBB: RBCC) works to develop new ways to capture a share of the fast-growing, $232 billion personalized medicine market, molecular pathology tests are rapidly transitioning from the laboratory to the clinic.

GEN magazine reported this month that clinical laboratories began billing for more than 100 molecular pathology tests using new CPT codes on the first of this year, replacing the previous stacked-code system. That means the valuable testing will be available to more patients through their insurance providers, opening up personalized medicine to a much wider audience.

"We're beginning to see patient care billers recognize that these tests work and provide value to the patient, the physician and the healthcare system," said RBCC CEO Patrick Brown. "That's a big breakthrough: Insurance coverage decisions and physician test usage are big drivers of clinical utility."

RBCC is developing a comprehensive media and marketing strategy designed to introduce new innovations and treatment options in a U.S. personalized medicine market poised for major expansion. PricewaterhouseCoopers predicts that the sector could grow to as much as $452 billion by 2015. One of the fastest-growing fields in the market is companion diagnostics, which could grow to as large as $42 billion by 2015, according to industry analysts TriMarkPublications.com.

RBCC has formed a biotech subsidiary, Rainbow BioSciences, to market and develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co.  (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Amgen Inc. (NAS: AMGN) .

For more information on RBCC's other biotech initiatives, please visit www.rainbowbiosciences.com/investors.html.

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Rainbow Coral Corp.
Patrick Brown, 850-269-7230
President and CEO

KEYWORDS:   United States  North America  Florida


The article RBCC: Insurance Companies, Researchers Drive Growth in Personalized Medicine originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading